
|Videos|July 22, 2021
Obesity Paradox in prostate cancer: potential explanations and next research steps
Author(s)Urology Times staff
Advertisement
Vinayak G. Wagaskar, MBBS, shares potential explanations for the “obesity paradox”—improved survival outcomes in patients with a high body mass index (BMI)—in patients with metastatic castration-resistant prostate cancer (mCRPC). A study presented at the 2021 European Association of Urology showed improved survival outcomes in obese patients with mCRPC compared with overweight and normal weight patients. In the video also discusses next steps with this research.
Wagaskar is an instructor of urology at Mount Sinai in New York City
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
3
FDA approves cefepime and zidebactam for complicated UTI
4
FDA updates in urology: May 2026
5











